A5033267787- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Polyomavirus and related diseases
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Cancer Treatment and Pharmacology
- Mesenchymal stem cell research
- Peptidase Inhibition and Analysis
- Renal Transplantation Outcomes and Treatments
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Hemoglobinopathies and Related Disorders
- Childhood Cancer Survivors' Quality of Life
- Hematological disorders and diagnostics
- Transplantation: Methods and Outcomes
- Cancer therapeutics and mechanisms
- Cytomegalovirus and herpesvirus research
- CNS Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Histone Deacetylase Inhibitors Research
City Of Hope National Medical Center
2014-2024
City of Hope
2012-2023
The University of Texas MD Anderson Cancer Center
2019
Duke Medical Center
2001-2016
Northwestern University
2016
University of Malaya
2011
Banner - University Medical Center Tucson
2011
Chang Gung Memorial Hospital
2011
Subang Jaya Medical Centre
2011
Mount Elizabeth Hospital
2011
PURPOSE: Three open-label, multicenter trials were conducted to evaluate the efficacy and safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories, Philadelphia, PA), an antibody-targeted chemotherapy agent, in patients with CD33-positive acute myeloid leukemia (AML) untreated first relapse. PATIENTS AND METHODS: The study population comprised 142 AML relapse no history antecedent hematologic disorder a median age 61 years. All received as 2-hour intravenous...
Despite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of myeloma, including those resistant to lenalidomide pomalidomide. In this phase 1–2 study, we administered oral mezigdomide combination dexamethasone patients relapsed refractory myeloma. The primary objectives 1 (dose-escalation cohort) were assess safety pharmacokinetics identify the dose...
Crenolanib is a second-generation tyrosine kinase inhibitor with activity against
Purpose: The goal of this study was to evaluate the feasibility, reliability, and validity a computer-based geriatric assessment via two methods electronic data capture ( SupportScreen REDCap) compared with paper-and-pencil among older adults cancer. Methods: Eligible patients were ≥ 65 years old, had cancer diagnosis, fluent in English. Patients randomly assigned one four arms, which they completed twice: (1) REDCap paper pencil sessions 1 2; (2) both sessions; (3) (4) sessions. evaluated....
Current conditioning regimens provide insufficient disease control in relapsed/refractory acute leukemia patients undergoing hematopoietic stem cell transplantation (HSCT) with active disease. Intensification of chemotherapy and/or total body irradiation (TBI) is not feasible because excessive toxicity. Total marrow and lymphoid (TMLI) allows for precise delivery increased intensity treatment via sculpting radiation to sites high burden or risk involvement, while sparing normal tissue. We...
We re p o rt here the transplantation of extensively purified "mobilized" peripheral blood CD34 + T h y -1 e m a t i c stem cells from 22 patients with u rrent or metastatic breast cancer.Patients were mobilized either high-dose granulocyte colony-stimulating factor (G-CSF) alone cyclophosphamide plus G-CSF.Median purity cell roduct at cry s rvation was 95.3% (range, 91.1%-98.3%),and viability 98.6% 96.5%-100%).After chemotherapy carmustine, cisplatin, and cyclophosphamide, median dose 11.3...
Patients and physicians may defer unrelated donor hematopoietic cell transplantation (HCT) as curative therapy because of the mortality risk associated with procedure. Therefore, it is important for to know current outcomes data when counseling potential candidates. To provide this information, we evaluated 15,059 transplant recipients between 2000 2009. We compared before after 2005 4 cohorts: age <18 years malignant diseases (n = 1920), ages 18 59 9575), ≥ 60 2194), nonmalignant 1370)....
Efficacy of PTCy after mismatched unrelated donor (MMUD) HCT is unknown. In this pilot clinical trial, we enrolled 38 patients with hematologic malignancies scheduled to undergo MMUD-HCT (≥6/8 HLA-matched donors) onto 1 2 conditioning strata: myeloablative using fludarabine and fractionated total body irradiation (n = 19) or reduced intensity fludarabine/melphalan 19). Graft source was peripheral blood stem cells (PBSCs), GVHD prophylaxis PTCy, tacrolimus, mycophenolate mofetil. Patients'...
Mean pixel intensity ratios, contrast parameters, and T1-T2 cross products relative to fat muscle were derived from T1-weighted T2-weighted images obtained at 1.5 T in 32 patients with non-Hodgkin lymphomas 20 Hodgkin disease. Lymphomas relatively homogeneous: Only 6% of the lesions had broad, bimodal, or skewed distributions intensities that could be attributed intrinsic heterogeneity. On average, hypointense slightly hyperintense but isointense images. Low-, intermediate-, high-grade...
Abstract BACKGROUND: Avascular necrosis (AVN) is a debilitating condition reported after chronic steroid use. The purpose of this study was to describe the magnitude risk in individuals who survived ≥1 years hematopoietic cell transplantation (HCT), and investigate role immunosuppressive agents such as prednisone, tacrolimus (FK506), mycophenolate mofetil (MMF), cyclosporine (CSA) development AVN HCT. METHODS: Using retrospective design, authors followed 1346 eligible patients for AVN....